Inofab Health valued at $15 million following investment from ERT and Karel

According to the information we have received, Inofab Health has received investment with a valuation of 15 million dollar from ERT, which works in the field of respiratory diseases clinical research technologies, and KAREL, a leading electronics producer in Turkey.
Inofab Health valued at $15 million following investment from ERT and Karel

We have previously mentioned Spirohome, which serves as a mobile health platform for chronic obstructive pulmonary disease and asthma patients, many times. The startup, which will continue under the Inofab Health brand, has received a new investment.

According to the information shared, Inofab Health has received a strategic investment from ERT, which operates in the field of respiratory diseases clinical research technologies, and KAREL, a leading electronics manufacturer in Turkey, with a valuation of 15 million dollar. Let us note that no information has been shared on the amount of investment.

Inofab Health, which offers digital health solutions for chronic respiratory diseases, has made the ultrasonic spirometer Spirohome it developed available, which is the first personal ultrasonic spirometer in the world, to its users in 45 countries since June 2019. As one of the Webrazzi Arena 2016 startup, Spirohome's progress over the years makes us happy.

During the COVID-19 pandemic, especially due to hospitals' spirometry laboratories being closed, measuring the lung volumes of patients from home has acquired far more importance. According to the information shared by the company, starting from this period, Inofab Health's Spirohome personal spirometer and Spirocloud remote tracking solutions have received strong demand from countries such as Australia, Germany, the United Kingdom, and Spain.

Inofab Health Team

Strategic importance of the investment

ERT, which took part in the research of 75% of all medications that received FDA approval in 2019, will use Spirohome in researches that measure the efficacy of respiratory medications all-across the world, especially in the United States.  Thanks to Spirohome, the participant patients' spirometry values will be monitored from home.

With this investment, Inofab Health aims to complete the FDA approval for the US market. The company, in addition to hardware products, also advances to provide system solutions with the newly-developed remote patient monitoring software called Spirocloud.

Lastly, that Inofab Health received its first seed investment, led by ACT Venture Partners, in 2017 and 2018 should not go unmentioned. 500 Istanbul and Growth Circuit VC also joined the seed investment round together with ACT Venture Partners.